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to obtain membrane-specific loss of function (iii) mice lacking the AF2
ligand-dependant-transcriptional function domain of ERα (AF2°) and (iv)
wild type (WT) mice. Hypertension was induced using Angiotensin II (Alzet
minipumps) and blood pressure measured using tail cuff. After 28 days vas-
cular structure and function were measured in vitro. Angiotensin II-induced
hypertension was greater in ERα-/- and in AF2° mice than in WT and C451A-
ERα mice. These data suggest that the protective effect of ERα against ele-
vated blood pressure involved nuclear AF2-mediated transcriptional functions
rather than MISS-mediated function. Changes in pressure were associated
with proportional changes in endothelium-dependent dilation and wall thick-
ness. Thanks to this work, we hope to better understand how ERα is able to
mediate the protective effects of estrogen against hypertension.
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Extracellular nucleotides are responsible for pleiotropic effects in the vas-
culature. Uracyl nucleotides are vasoactive and trophic agents and promote
inflammation. The participation of specific P2 receptors in these effects
remains undefined and their potential contribution in arterial hypertension is
unknown. Objective: To evaluate the contribution of the UDP receptor P2Y6
in hypertension in mouse. Methods: Arterial contraction was evaluated using
a wire myograph. Blood pressure was measured following nucleotides iv infu-
sion and experimental hypertension was induced either by Angiotensine-II
(Ang-II 1mg/kg/j) or DOCA-salt (1%) in uni-nephrectomized mice. Histolog-
ical approaches, immunofluorescence and RTqPCR were used to evaluate the
nature of vascular remodeling. Results: P2Y6 displayed the highest arterial
expression level among other P2Y receptors. Contraction of conductance (tho-
racic aorta) and resistance (mesenteric) arteries was abrogated in P2ry6-/-
mice in response to UDP and UTP while other vasoconstrictor induced normal
responses. P2Y6 receptor triggered a moderated intracellular calcium increase
while RhoA (calcium facilitating pathway) activation was abrogated in P2ry6-
/- mice. Both genetic deletion and pharmacological blockade of P2Y6 receptor
abolished Ang-II-induced blood pressure increase (40 mmHg in wild type
mice). By contrast, hypertensive response in DOCA-salt was equivalent in
both genotypes. Following Ang-II treatment, P2ry6-/- mice developed a
reduced arterial hypertrophic remodeling and fibrosis but equivalent immune
cell recruitment/infiltration compared to wild type. These changes were cor-
roborated to reduced mRNA expressions of TGFβ and NADPH oxidase sub-
units. Conclusions: Vascular P2Y6 receptor contributes to exaggerated
vascular tone, hypertrophy and fibrosis in the context of Ang-II-dependent
hypertension. Its absence or pharmacological blockade limits vascular
damages and prevents blood pressure increase associated to hypertension.
0356
Disseminated arterial calcification and enhanced myogenic response
are associated with Abcc6 deficiency in a mouse model of pseudoxan-
thoma elasticum
Gilles Kauffenstein (1), Anne Pizard (2), Yannick Le Corre (1), Emilie
Vessières (1), Linda Grimaud (1), Bertrand Toutain (1), Carlos Labat (2),
Yves Mauras (3), Theo G. Gorgels (4), Arthur A. Bergen (4), Olivier Le
Saux (5), Patrick Lacolley (2), Georges Lefthériotis (1), Daniel Henrion (1),
Ludovic Martin (1)
(1) Université d’Angers, UMR CNRS 6214 INSERM U1083, Angers,
France – (2) Faculté de Médecine, INSERM U1116, Vandoeuvre-Les-
Nancy, France – (3) CHU Angers, Laboratoire de Pharmacologie Toxico-
logie, Angers, France – (4) Netherlands Institute for Neuroscience, Mole-
cular Ophthalmogenetics, Amsterdam, Pays-Bas – (5) John A. Burns
School of Medicine, Cell and Molecular Biology, Honolulu, Etats-Unis
Beside calcification, the impact of ABCC6 deficiency on the vasculature
remains unclear. We investigated arterial structure and function in Abcc6-/-
mice, a model of the human Pseudoxanthoma Elasticum (PXE). Arterial cal-
cium accumulation determined by atomic absorption spectrometry was 1.5 –
to 2-fold higher in Abcc6-/- than in wild-type mice. Calcium also accumulated
locally leading to a specific punctuated pattern. Abcc6-/- mesenteric arteries
mounted on a wire myograph displayed slight increase in arterial vaso-
constrictor tone in response to phenylephrine and thromboxane A2. Interest-
ingly, myogenic tone (Bayliss effect) determined using a pressure myograph
was significantly elevated in Abcc6-/- compared to wild type arteries. Arterial
blood pressure was not significantly modified in Abcc6-/- animals, despite
higher variability. These changes were accompanied with deregulated gene
expression (RTqPCR) in both liver and resistance arteries. Old Abcc6-/-
mouse mesenteric arteries expressed markers of both osteogenic (Runx2, opn)
and chondrogenic lineage (Sox9, col2a1). Surprisingly Enpp1 and Alpl genes
encoding ectonucleotide pyrophosphatase/phosphodiesterase 1 and alkaline
phosphatase were deregulated within Abcc6-/- liver and this was corroborated
with reduced alkaline phosphatase circulating levels in PXE patients. As a
conclusion, scattered calcium depositions result from osteochondrogenic trans-
differentiation of vascular cells. The lower elasticity and increased myogenic
tone evidenced in aged Abcc6-/- mice suggest a reduced control of local blood
flow, which in turn may alter vascular homeostasis. Our findings argue in
favor of a deregulated arterial function and may help to decipher conse-
quences of ABCC6 deficiency since PXE is a significant risk factor for small
vessel disease and particularly ischemic stroke.
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Objective: The hypothesis that hypertension confers a hypercoagulable
state arises from the complications associated with hypertension, stroke and
myocardial infarction. Our objective was to determine whether spontaneous
hypertension causes changes in the thrombin generating capacity of the vas-
cular wall.
Approach and Results: We used spontaneously hypertensive rats (SHR)
compared with Wistar rats. The addition of thoracic aorta rings of SHR to a
Wistar or SHR plasma pool resulted in a greater increase in thrombin genera-
tion compared to the addition of equivalent rings from Wistar. Comparison of
5 week-old and 12 week-old rats indicate that established hypertension is
required to induce increased thrombin generation within the vessel wall.
Whereas no difference was observed for endothelial cells, thrombin formation
was higher at the surface of cultured aortic smooth muscle cells (SMCs) from
SHR than from Wistar. Exposure of negatively-charged phospholipids was
higher on SHR than on Wistar aortic rings as well as on SMCs. Tissue factor
activity was higher in SHR SMCs. Twelve week-old SHR exhibited acceler-
ated FeCl3-induced thrombus formation in carotid arteries and the resulting
occlusive thrombi are disaggregated by blockade of glycoprotein Ibα-von
Willebrand factor interactions. SHR SMCs were more sensitive to thrombin-
induced proliferation than Wistar SMCs. This cellular effect was totally
abolished by a protease-activated receptor 1 inhibitor.
Conclusions: The prothrombotic phenotype of the SHR vessel wall was
due to the ability of SMCs to support greater thrombin generation and resulted
in accelerated occlusive thrombus formation after arterial injury, which is sen-
sitive to glycoprotein Ibα-von Willebrand factor inhibitors.
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The renin-angiotensin system has a key role in cardiovascular homeostasis,
mainly through activation of angiotensin II type 1 (AT1R) and type 2 (AT2R)
© Elsevier Masson SAS. All rights reserved.
 
Archives of Cardiovascular Diseases Supplements (2015) 7, 187-189 189
receptors. Although AT2R opposes the effects of AT1R, with vasodilator and
antitrophic properties, its effect in diabetes remains debated. Thus we
determined the role of AT2R in endothelium-mediated dilation in a mouse
model of type 1 diabetes. Diabetes was induced in three-month-old mice by
streptozotocin (150mg/kg, ip). After 45 days, mesenteric resistance arteries
were isolated and mounted on a wire myograph to measure vascular reactivity.
The absence of AT2R reduced glucose tolerance and body weight and
increased STZ-induced hyperglycemia, hyperinsulinemia, creatiniemia, blood
thromboxaneA2, PGF2alpha and isoprostane. AT2R, COX-2 and NADPH-
oxidase subunits (gp91phox and p22phox) gene expression were higher in
arteries of diabetic mice than in control animals. COX-2 level and oxidative
stress were also higher in mesenteric and renal arteries in AT2R-/- mice.
Endothelium-dependent relaxation, reduced in diabetic mice arteries, was
normalized after cycloxygenase-2 (COX-2) (CAY10404) blockade or ROS
reduction with tempol plus catalase in both AT2R-/- and AT2R+/+ mice.
AT2R-dependent dilation in isolated perfused mesenteric arteries was greater
in diabetic mice than in control animals.
Thus, in a model of type 1 diabetes AT2R reduces the severity of diabetes
possibly through a reduction of the production of ROS and COX-2-derived
vasoconstrictor agents.
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